On May 11, 2018, the Institutional Review Board an
Post# of 110
(Total Views: 469)
Posted On: 05/16/2018 3:29:10 PM
On May 11, 2018, the Institutional Review Board and Scientific Review Committee at the Dana-Farber Cancer Institute approved the clinical trial of ProscaVax™, the Company’s lead immunotherapy product from its platform, at Beth Israel Deaconess Medical Center and Dana-Farber. The Principal Investigator is Rupal Bhatt, MD, PhD with Co-Investigator Glenn Bubley, MD. It is expected that the clinical trial will be enrolling patients in the near future. The clinical trial is titled: “A Phase 2, Randomized Study of Proscavax, a PSA/IL-2/ GM-CSF Vaccine, in Treatment-naive Patients with Clinically Localized Prostate Cancer Versus an Active Surveillance Strategy”.
8k just filed
8k just filed
(1)
(0)Theratechnologies Inc. (THER) Stock Research Links
Scroll down for more posts ▼